SOLOIST-WHF trial

The SOLOIST trial assessed the efficacy and safety of sotagliflozin in patients with heart failure and type 2 diabetes. This module details the results.

SOLOIST-WHF trial
Rate this content
  • SOLOIST-WHF trial
  • SOLOIST-WHF trial
  • Sotagliflozin is a dual SGLT1 and SGLT2 inhibitor1
  • SOLOIST-WHF: study design1,2
  • SOLOIST-WHF: key inclusion and exclusion criteria
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go